For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) closed the day trading at $7.48 down -11.69% from the previous closing price of $8.47. In other words, the price has decreased by -$11.69 from its previous closing price. On the day, 3.31 million shares were traded. AUPH stock price reached its highest trading level at $8.48 during the session, while it also had its lowest trading level at $7.45.
Ratios:
For a better understanding of AUPH, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.23 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.02. For the most recent quarter (mrq), Quick Ratio is recorded 5.26 and its Current Ratio is at 5.93. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.18.
Oppenheimer Upgraded its Perform to Outperform on December 10, 2021, whereas the target price for the stock was revised from $33 to $31.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 07 ’25 when Keenan Greg sold 8,305 shares for $8.23 per share. The transaction valued at 68,350 led to the insider holds 153,484 shares of the business.
Greenleaf Peter sold 195,593 shares of AUPH for $1,564,744 on Mar 03 ’25. The Chief Executive Officer now owns 1,953,892 shares after completing the transaction at $8.00 per share. On Mar 04 ’25, another insider, Greenleaf Peter, who serves as the Chief Executive Officer of the company, sold 164,947 shares for $7.92 each. As a result, the insider received 1,306,380 and left with 1,788,945 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUPH now has a Market Capitalization of 1010577920 and an Enterprise Value of 909657408. As of this moment, Aurinia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 27.08, and their Forward P/E ratio for the next fiscal year is 9.87. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.09 while its Price-to-Book (P/B) ratio in mrq is 2.94. Its current Enterprise Value per Revenue stands at 3.678 whereas that against EBITDA is 14.69.
Stock Price History:
The Beta on a monthly basis for AUPH is 1.17, which has changed by 0.36745882 over the last 52 weeks, in comparison to a change of 0.11937654 over the same period for the S&P500. Over the past 52 weeks, AUPH has reached a high of $10.67, while it has fallen to a 52-week low of $5.20. The 50-Day Moving Average of the stock is -7.50%, while the 200-Day Moving Average is calculated to be -6.80%.
Shares Statistics:
Over the past 3-months, AUPH traded about 1.34M shares per day on average, while over the past 10 days, AUPH traded about 2093660 shares per day. A total of 137.75M shares are outstanding, with a floating share count of 119.37M. Insiders hold about 11.64% of the company’s shares, while institutions hold 45.08% stake in the company. Shares short for AUPH as of 1749772800 were 10530635 with a Short Ratio of 7.85, compared to 1747267200 on 10877775. Therefore, it implies a Short% of Shares Outstanding of 10530635 and a Short% of Float of 8.520000399999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Current recommendations for the stock of the company come from 5.0 analysts. The consensus estimate for the next quarter is $0.14, with high estimates of $0.21 and low estimates of $0.1.
Analysts are recommending an EPS of between $0.76 and $0.45 for the fiscal current year, implying an average EPS of $0.59. EPS for the following year is $0.76, with 5.0 analysts recommending between $1.19 and $0.54.
Revenue Estimates
6 analysts predict $64.27M in revenue for the current quarter. It ranges from a high estimate of $65.5M to a low estimate of $63.66M. As of the current estimate, Aurinia Pharmaceuticals Inc’s year-ago sales were $57.19MFor the next quarter, 6 analysts are estimating revenue of $64.5M. There is a high estimate of $65.03M for the next quarter, whereas the lowest estimate is $63.4M.
A total of 6 analysts have provided revenue estimates for AUPH’s current fiscal year. The highest revenue estimate was $260.9M, while the lowest revenue estimate was $256.2M, resulting in an average revenue estimate of $258.98M. In the same quarter a year ago, actual revenue was $235.13MBased on 6 analysts’ estimates, the company’s revenue will be $307.09M in the next fiscal year. The high estimate is $355.79M and the low estimate is $290M.
